老年经典霍奇金淋巴瘤患者老年学健康状态与真实世界结局的多中心分析
该多中心回顾性分析纳入10个美国学术医疗中心2010-2018年244例≥60岁经典霍奇金淋巴瘤患者,评估治疗模式与结局。中位年龄68岁,63%为晚期,仅日常生活活动能力(ADL)丧失预测更短的无进展生存(PFS)和总生存(OS)。多数患者接受传统化疗,其PFS和OS显著优于其他疗法,60-69岁与≥70岁生存相似。
要点
- ADL丧失是老年cHL患者PFS和OS的独立不良预测因素。
- 传统化疗方案在适合的老年患者中仍为标准治疗,生存优于其他疗法。
- CIRS-G≥10或老年综合征者早期因毒性停药风险更高。
核心结论
- 传统化疗方案在适合的老年cHL患者中仍为标准治疗,老年评估对定义治疗适合性至关重要。
研究设计与样本
- 多中心回顾性分析,纳入10个美国学术医疗中心2010-2018年244例≥60岁经典霍奇金淋巴瘤患者。
主要发现
- 中位年龄68岁,63%为晚期(III/IV),96% ECOG体能状态0-2,12%记录有≥1项ADL丧失,18%(n=44)CIRS-G总分≥10。
- 多变量Cox模型显示仅ADL丧失预测更短PFS(HR 2.13,P=.007)和OS(HR 2.52,P=.02)。
- 83%(n=203)接受传统化疗,包括ABVD(56%)、AVD(14%)、AVD联合维布妥昔单抗(BV;9%);与传统方案相比,其他疗法PFS(HR 0.46,P=.0007)和OS(HR 0.31,P=.0003)更差。
- 传统化疗后60-69岁与≥70岁生存相似:PFS HR 0.88,P=.63;OS HR 0.73,P=.55。
- CIRS-G≥10(28% vs 12%,P=.016)或记录老年综合征(28% vs 13%,P=.02)者早期因毒性停药更常见。
关键数值与推荐
- ADL丧失预测更短PFS(HR 2.13,P=.007)和OS(HR 2.52,P=.02)。
- 传统化疗 vs 其他疗法:PFS HR 0.46(P=.0007),OS HR 0.31(P=.0003)。
- 60-69岁 vs ≥70岁传统化疗后:PFS HR 0.88(P=.63),OS HR 0.73(P=.55)。
- CIRS-G≥10者早期停药28% vs 12%(P=.016);老年综合征者28% vs 13%(P=.02)。
- 竞争风险分析:传统治疗改善疾病相关生存(HR 0.29,P=.02),高CIRS-G或老年综合征者非疾病/治疗死亡更高。
临床怎么用
- 对适合的老年cHL患者,传统化疗(如ABVD、AVD、AVD-BV)仍可作为标准治疗选择。
- 治疗前应进行老年评估,包括ADL和CIRS-G,以识别适合传统化疗的患者。
- 对CIRS-G≥10或存在老年综合征者,需警惕早期因毒性停药风险。
局限性
- 回顾性研究设计,可能存在选择偏倚和未测量混杂因素。
- 样本量有限(244例),部分亚组分析效能不足。
- 原文未报告具体治疗调整方案及长期随访细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We performed a multicenter retrospective analysis across 10 US academic medical centers to evaluate treatment patterns and outcomes in patients age ≥60 years with classic Hodgkin lymphoma (cHL) from 2010-2018. Among 244 eligible patients, median age was 68, 63% had advanced stage (III/IV), 96% had Eastern Cooperative Oncology Group performance status (PS) 0-2, and 12% had documented loss of ≥1 activity of daily living (ADL). Medical comorbidities were assessed by the Cumulative Illness Rating Scale-Geriatric (CIRS-G), where n = 44 (18%) had total scores ≥10. Using multivariable Cox models, only ADL loss predicted shorter progression-free (PFS; hazard ratio [HR] 2.13, P = .007) and overall survival (OS; HR 2.52, P = .02). Most patients (n = 203, 83%) received conventional chemotherapy regimens, including doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD; 56%), AVD (14%), and AVD with brentuximab vedotin (BV; 9%). Compared to alternative therapies, conventional regimens significantly improved PFS (HR 0.46, P = .0007) and OS (HR 0.31, P = .0003). Survival was similar following conventional chemotherapy in those ages 60-69 vs ≥70: PFS HR 0.88, P = .63; OS HR 0.73, P = .55. Early treatment discontinuation due to toxicity was more common with CIRS-G ≥10 (28% vs 12%, P = .016) or documented geriatric syndrome (28% vs 13%, P = .02). A competing risk analysis demonstrated improved disease-related survival with conventional therapy (HR 0.29, P = .02) and higher mortality from causes other than disease or treatment with high CIRS-G or geriatric syndromes. This study suggests conventional chemotherapy regimens remain a standard of care in fit older patients with cHL, and highlights the importance of geriatric assessments in defining fitness for cHL therapy going forward.
引用
- Orellana-Noia VM, Isaac K, Malecek MK, et al. Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. Blood Adv. 2021. PMID: 34448831. doi:10.1182/bloodadvances.2021004645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。